Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22107444 | 0.92 | ADORA2A (0.35) | ADORA2AADORA2BADORA1PIK3CDPI4KA | |
| SCHEMBL22349649 | 0.87 | TLR7 (0.32) | ADORA2AADORA2BADORA1PI4KAPI4K2B | |
| SCHEMBL21998567 | 0.85 | TLR7 (0.35) | ADORA2AADORA2BADORA1 | |
| SCHEMBL24633433 | 0.84 | TLR7 (0.33) | ADORA2AADORA2BADORA1PI4KAPI4K2B | |
| SCHEMBL21078631 | 0.82 | ADA (0.38) | — | |
| SCHEMBL24235860 | 0.79 | ADA (0.39) | — | |
| SCHEMBL24117695 | 0.78 | TLR7 (0.36) | — | |
| SCHEMBL15340435 | 0.78 | ACVRL1 (0.39) | ADORA2AADORA2BADORA1PIK3CDPI4KA | |
| SCHEMBL21758936 | 0.76 | PI4KB (0.35) | ADORA2AADORA2BADORA1PIK3CDPI4KA | |
| SCHEMBL21636967 | 0.71 | TLR7 (0.39) | ADORA2AADORA2BADORA1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | ADORA2A 69/4885ADORA2B 147/4885ADORA1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.